Fibrosis-4指数基于日本一般人群的大规模数据有效预测慢性肝

StephenW

Fibrosis-4指数基于日本一般人群的大规模数据有效预测慢性肝炎和肝硬化的发展

    山道信武、岛本武史、奥信和也、西川隆子、松崎广孝、矢嘉诚一、高桥真美、和田良一、小池和彦和藤城光弘

科学报告第 12 卷，文章编号：20357 (2022) 引用这篇文章

    2 高度计

    指标详情

抽象的

需要一种非侵入性方法来评估纤维化阶段和非酒精性脂肪性肝病 (NAFLD) 的风险分层。共调查了1990年至2019年期间接受健康检查的416,066名一般健康的受试者。从 1990 年代（21.9%）到 2000 年代（37.1%），脂肪肝患病率大幅增加，但在 2001-2010 年（39.2%）和 2011-2019 年（35.5%）之间没有显着变化。在这 30 年中，高 FIB-4 指数（≥2.67）和平均体重指数（BMI）的比率没有显着变化。脂肪肝与 BMI 显着相关，但与酒精摄入量或 FIB-4 指数无关。慢性肝炎或肝硬化发展的 Cox 回归分析确定，没有脂肪肝的受试者发生慢性肝炎和肝硬化的风险高于脂肪肝受试者（风险比 [HR] = 0.09；95% 置信区间 [CI] , 0.03-0.22, p <0.001 和 HR=0.04; 95% CI, 0.01-0.26, p =0.001, 分别), 并且在具有高 FIB-4 指数 (≥ 2.67) 的受试者中比没有它的受试者大得多 ( HR=78.6；95% CI，29.0–213.1，p <0.001 和 HR=5950.7；95% CI，761.7–46,491.4，p <0.001）。 Cox 比例风险回归的调整后生存曲线进一步强化了这些结果。总之，FIB-4 指数是一般人群慢性肝炎和肝硬化发展的有用指标。

StephenW

Fibrosis-4 index efficiently predicts chronic hepatitis and liver cirrhosis development based on a large-scale data of general population in Japan

    Nobutake Yamamichi, Takeshi Shimamoto, Kazuya Okushin, Takako Nishikawa, Hirotaka Matsuzaki, Seiichi Yakabi, Mami Takahashi, Ryoichi Wada, Kazuhiko Koike & Mitsuhiro Fujishiro 

Scientific Reports volume 12, Article number: 20357 (2022) Cite this article

    2 Altmetric

    Metrics details

Abstract

A non-invasive method to evaluate the fibrosis stage and the risk stratification of non-alcoholic fatty liver disease (NAFLD) is required. A total of 416,066 generally healthy subjects who underwent health check-ups between 1990 and 2019 were investigated. Fatty liver prevalence greatly increased from the 1990s (21.9%) to the 2000s (37.1%) but showed no considerable change between 2001–2010 (39.2%) and 2011–2019 (35.5%). During the 30 years, the rate of high FIB-4 index (≥2.67) and mean body mass index (BMI) did not markedly change. Fatty liver was significantly associated with BMI, but not with alcohol intake or FIB-4 index. Cox regression analyses for development of chronic hepatitis or liver cirrhosis identified that the risk of developing chronic hepatitis and liver cirrhosis was higher in subjects without fatty liver than in those with it (hazard ratio [HR]=0.09; 95% confidence interval [CI], 0.03–0.22, p <0.001 and HR=0.04; 95% CI, 0.01–0.26, p =0.001, respectively), and much larger in subjects with a high FIB-4 index (≥ 2.67) than in those without it (HR=78.6; 95% CI, 29.0–213.1, p <0.001 and HR=5950.7; 95% CI,761.7–46,491.4, p <0.001, respectively). Adjusted survival curves for Cox proportional hazards regression further reinforced these results. In conclusion, the FIB-4 index is a useful indicator of chronic hepatitis and liver cirrhosis development in the general population.

StephenW

https://www.nature.com/articles/s41598-022-24910-2.pdf